Cost-effectiveness Analysis of Combined Valsartan Medication in the Treatment of Chronic Hepatitis B Fibrosis

Zhu Lingyun, Xu Ling, Tong Ning, Yu Fei, Ma Li

Chinese Pharmaceutical Affairs ›› 2017, Vol. 31 ›› Issue (3) : 258-262.

Chinese Pharmaceutical Affairs ›› 2017, Vol. 31 ›› Issue (3) : 258-262. DOI: 10.16153/j.1002-7777.2017.03.005
Pharmacoeconomics

Cost-effectiveness Analysis of Combined Valsartan Medication in the Treatment of Chronic Hepatitis B Fibrosis

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2017, 31(3): 258-262 https://doi.org/10.16153/j.1002-7777.2017.03.005

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-7
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉